SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Universal Health Services, Inc. (UHS) trades at a trailing P/E of 8.0, forward P/E of 7.8. Trailing earnings yield is 12.48%, forward earnings yield 12.89%. PEG 0.21 (Peter Lynch undervalued ≤1.0). Graham Number is $247.78.
Criteria proven by this page:
- VALUE (91/100, Pass) — P/E is below market average (8.0); PEG ≤ 1.0 — Peter Lynch undervalued (0.21); analyst target implies upside (+35%); earnings yield beats bond yields (12.48%).
- Forward P/E 7.8 (down from trailing 8.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.21 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 12.48% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 12.89% as earnings recover.
- Analyst consensus target $245.67 (+35% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 74/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
91/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — UHS
Valuation Multiples
P/E (TTM)8.0
Forward P/E7.8
PEG Ratio0.21
Forward PEG5.17
P/B Ratio1.64
P/S Ratio0.69
EV/EBITDA6.3
Per Share Data
EPS (TTM)$23.42
Forward EPS (Est.)$23.44
Book Value / Share$116.53
Revenue / Share$273.11
FCF / Share$13.06
Yields & Fair Value
Earnings Yield12.48%
Forward Earnings Yield12.89%
Dividend Yield0.43%
Graham Number$247.78
SharesGrow IV$441.48 (+142.6%)
Analyst Target$245.67 (+35%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
14.7 |
3.07 |
2.28 |
1.06 |
0.38% |
| 2017 |
14.4 |
1.63 |
2.17 |
1.04 |
0.35% |
| 2018 |
13.9 |
2.19 |
2.02 |
1.01 |
0.34% |
| 2019 |
15.6 |
1.63 |
2.31 |
1.12 |
0.42% |
| 2020 |
12.4 |
0.60 |
1.85 |
1.01 |
0.15% |
| 2021 |
10.8 |
1.28 |
1.76 |
0.85 |
0.62% |
| 2022 |
15.2 |
-0.66 |
1.74 |
0.77 |
0.57% |
| 2023 |
14.7 |
1.21 |
1.72 |
0.74 |
0.53% |
| 2024 |
10.5 |
0.16 |
1.79 |
0.75 |
0.45% |
| 2025 |
9.3 |
0.26 |
1.91 |
0.80 |
0.37% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.14 |
$9.77B |
$702.41M |
7.2% |
| 2017 |
$7.81 |
$10.41B |
$752.3M |
7.2% |
| 2018 |
$8.32 |
$10.77B |
$779.71M |
7.2% |
| 2019 |
$9.13 |
$11.38B |
$814.85M |
7.2% |
| 2020 |
$10.99 |
$11.56B |
$943.95M |
8.2% |
| 2021 |
$11.82 |
$12.64B |
$991.59M |
7.8% |
| 2022 |
$9.14 |
$13.4B |
$675.61M |
5% |
| 2023 |
$10.23 |
$14.28B |
$717.8M |
5% |
| 2024 |
$16.82 |
$15.83B |
$1.14B |
7.2% |
| 2025 |
$23.10 |
$17.36B |
$1.49B |
8.6% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$23.44 |
$22.34 – $24.51 |
$18.48B |
$18.41B – $18.57B |
11 |
| 2027 |
$25.57 |
$23.79 – $28.09 |
$19.39B |
$19.05B – $19.66B |
11 |
| 2028 |
$28.25 |
$26.68 – $31.03 |
$20.33B |
$20.29B – $20.37B |
6 |
| 2029 |
$28.77 |
$27.74 – $29.24 |
$20.54B |
$19.98B – $20.8B |
4 |
